CPT 43242 is most relevant to advanced gastroenterology workflows where documentation, clinical coordination and payer alignment have a direct impact on reimbursement. It's often seen in hospital-based endoscopy units and complex diagnostic pathways in specialty practices.
These processes need to be structured to reduce disruptions to claims and exposure to audits by the payers, and to ensure that everyone is communicating clearly and correctly. Standardized billing frameworks, like those created for specialized practices from OBGYN Medical Billing, are essential in high-complexity procedures to ensure consistency and minimize administrative mistakes.
CPT 43242 Description
“Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis).”
CPT 43242 is a combination of CPT 43240 and CPT 46340 to combine a flexible endoscope with EUS for evaluation of deeper layers of the upper GI tract. The ultrasound feature can provide detailed imaging beyond the mucosal surface, providing the opportunity to assess lesions that are not well characterized with routine endoscopy.
Under ultrasound guidance, the fine needle aspiration or biopsy is performed on suspicious lesions, masses, lymph nodes or submucosal changes during the same session to collect tissue samples. This allows the procedure to be diagnostic and tissue acquiring within a single integrated service.
CPT 43242 Includes
- Upper GI endoscopy (EGD)
- Endoscopic ultrasound (EUS) examination
- Ultrasound-guided fine needle aspiration (FNA) or biopsy
- Evaluation of esophagus, stomach, duodenum or jejunum
- Sampling of lesions, cysts, or lymph nodes
CPT 43242 Does NOT Include
- Reporting of EGD or EUS services separately.
- Additional codes for biopsy of the same target lesion.
- Treatment like polypectomy or ablation
- Endoscopic components that are unbundled.
Reimbursement Insights for CPT 43242
CPT 43242 is reimbursed at a higher amount than the typical upper gastrointestinal endoscopy codes, since this procedure includes both the advanced imaging and also ultrasound guided tissue sampling. It is deemed a high complexity diagnostic test by payers and payment is linked to documentation of good quality and medical necessity criteria. Endoscopic ultrasound with biopsy is usually covered by Medicare and commercial insurance if there are clear clinical indications for it.
Key reimbursement considerations
- Covered if medical necessity for biopsy by EUS is clearly documented.
- Higher reimbursement due to combined diagnostic imaging and tissue acquisition
- Payment varies based on the site of service (hospital outpatient vs ASC vs physician setting)
- Global period which is 000 days
- Instructional materials that integrate bundled code (EUS + FNA/biopsy).
- Reimbursement differences due to payer policies and geographic location
- Denials frequently happen as a result of inadequate documentation or unbundling.
Applicable Modifiers for CPT 43242
Appropriate modifier selection is important because incorrect application can lead to denials, post-payment audits, or downcoding of the claim.
Commonly used modifiers
- -22 (Increased Procedural Services):
When the procedure is more demanding than usual, e.g. multiple difficult biopsy sites or technically challenging anatomy. The increased complexity needs to be justified in the supporting documentation. - -52 (Reduced Services)
Used for partial or shortened procedure than the standard service. This can be due to some examination or incomplete sampling. - -53 (Discontinued Procedure)
Used when the procedure is stopped due to patient instability, technical difficulty, or clinical safety concerns before completion of planned services. - -59 / X{EPSU} (Distinct Procedural Service):
Used only when a clearly separate and distinct procedure is performed that meets payer criteria for unbundling. - -26 / TC (Professional / Technical Component):
Used when reporting only the professional interpretation or the technical portion of the service, depending on billing structure.
Documentation Requirements for CPT 43242
The documentation should clearly demonstrate why EUS-guided biopsy was required instead of standard endoscopy, along with detailed procedural findings and sampling information.
Required documentation elements
- Evident indication to undertake EUS fine needle aspiration or biopsy.
- Medical necessity justifying the need for tissue diagnosis.
- A detailed description of the lesions, masses, or abnormal findings.
- Specific anatomical site(s) assessed (esophagus, stomach, duodenum/jejunum)
- The extent of the endoscopic ultrasound examination done
- The number of passes and samples made.
- Technique for obtaining tissue (FNA or biopsy)
- What matters most for the sample is that it is collected under ultrasound guidance which has been confirmed.
- Endoscopic findings and impression at the end of the procedure.
- In any intra-procedural complications or limitations
- When applicable, providing pathology specimens for analysis.
- Authored and finalized report on endoscopy procedure.
Incomplete or vague reporting of EUS findings or biopsy details is a common reason for claim denials and audit queries.
Clinical Scenarios for CPT 43242
Scenario 1: Pancreatic Mass Evaluation with EUS-FNA
A 60-year-old man complains of abdominal pain and loss of weight. Imaging tests show a growth (mass) in the head of the pancreas. The gastroenterologist uses upper endoscopy to carry out endoscopic ultrasound and finds a hypoechoic lesion in the pancreas. FNA is done to take tissue samples for cytological examination.
→ Coding Outcome: CPT 43242
→ Rationale: EUS examination with ultrasound guided FNA of a pancreatic lesion is a supportive service for reporting CPT 43242.
Scenario 2: Esophageal Cancer Staging with Lymph Node Biopsy
A patient with definitively diagnosed esophageal carcinoma has an endosonogram which is useful for staging. The doctor checks the depth of the tumour and looks for enlarged lymph nodes around the oesophagus. Fine needle aspiration is done on the lymph nodes for pathological staging.
→ Coding Outcome: CPT 43242
→ Rationale: Comprehensive EUS with lymph node sampling for cancer staging meets criteria for CPT 43242.
Scenario 3: Gastric Submucosal Lesion Evaluation
A patient is referred for evaluation of a subepithelial lesion in the stomach found at a previous endoscopy. Endoscopic ultrasound is used to determine the depth of the lesion and where it is from. Pathological diagnosis is achieved by taking tissue samples under ultrasound guidance.
→ Coding Outcome: CPT 43242
→ Rationale: EUS evaluation and ultrasound guided biopsy of the submucosal lesion of the stomach assist in the reporting of CPT 43242.
Scenario 4: Procedure Discontinued Due to Clinical Instability
Planned endoscopic ultrasound for the assessment of a pancreatic lesion. The patient becomes unstable in the process and the doctor does not manage to perform the fine needle aspiration procedure. The process is halted for safety reasons for the patient.
→ Coding Outcome: CPT 43242-53
→ Rationale: The procedure was discontinued prior to completion because the clinical status of the patient was unstable, supporting modifier -53 usage.
BillingFreedom Known For Gastroenterology Medical Billing Built on High-Accuracy Revenue Cycle Performance
Billing Freedom have a strong emphasis on assisting with high complexity gastrointestinal (GI) procedures like CPT 43242, where accuracy in documentation and Gastroenterology Billing coding directly influences reimbursement results. In order to process claims cleanly, there must be consistency in the way that advanced endocrine services are reported, medically necessary and coded according to specific rules applied by the payers.
When endoscopic ultrasound with fine needle aspiration or biopsy is performed, it is particularly critical for the documentation to be clear, as even slight discrepancies can result in denials or delayed payments. We focus on enhancing documentation validation, coding accuracy checks and compliance-based review processes to minimize such risks throughout specialty GI workflows.
Key Revenue Cycle Performance Metrics
- First-pass claim acceptance rate: 97%–99%
- Preventable denial rate: less than 1%
- Clean claim submission accuracy: 95%+
- Internal coding validation accuracy: 98%+
This strategy will assist gastroenterology practices to achieve more stable reimbursement for their practices and meet compliance requirements for advanced endoscopic coding, including CPT 43242.
For more details about our best Gastroenterology medical billing services, please don't hesitate to contact us by email at info@billingfreedom.com or call us at +1 (855) 415-3472.
Your financial tranquility is our priority!
Related ICD-10-CM Codes
ICD-10-CM Codes
C15.3 - Malignant neoplasm of upper third of esophagus
C15.4 - Malignant neoplasm of middle third of esophagus
C15.5 - Malignant neoplasm of lower third of esophagus
C15.8 - Malignant neoplasm of overlapping sites of esophagus
C15.9 - Malignant neoplasm of esophagus, unspecified
C16.1 - Malignant neoplasm of fundus of stomach
C16.2 - Malignant neoplasm of body of stomach
C16.3 - Malignant neoplasm of pyloric antrum
C16.4 - Malignant neoplasm of pylorus
C16.5 - Malignant neoplasm of lesser curvature of stomach, unspecified
C16.6 - Malignant neoplasm of greater curvature of stomach, unspecified
C16.8 - Malignant neoplasm of overlapping sites of stomach
C16.9 - Malignant neoplasm of stomach, unspecified
C17.0 - Malignant neoplasm of duodenum
C17.1 - Malignant neoplasm of jejunum
C17.8 - Malignant neoplasm of overlapping sites of small intestine
C17.9 - Malignant neoplasm of small intestine, unspecified
C24.0 - Malignant neoplasm of extrahepatic bile duct
C24.1 - Malignant neoplasm of ampulla of Vater
C24.8 - Malignant neoplasm of overlapping sites of biliary tract
C25.1 - Malignant neoplasm of body of pancreas
C25.2 - Malignant neoplasm of tail of pancreas
C25.3 - Malignant neoplasm of pancreatic duct
C25.7 - Malignant neoplasm of other parts of pancreas
C25.8 - Malignant neoplasm of overlapping sites of pancreas
C25.9 - Malignant neoplasm of pancreas, unspecified
C26.9 - Malignant neoplasm of ill-defined sites within the digestive system
C45.1 - Mesothelioma of peritoneum
C45.9 - Mesothelioma, unspecified
C47.3 - Malignant neoplasm of peripheral nerves of thorax
C47.4 - Malignant neoplasm of peripheral nerves of abdomen
C48.1 - Malignant neoplasm of specified parts of peritoneum
C48.8 - Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49.3 - Malignant neoplasm of connective and soft tissue of thorax
C49.4 - Malignant neoplasm of connective and soft tissue of abdomen
C76.1 - Malignant neoplasm of thorax
C76.2 - Malignant neoplasm of abdomen
C77.2 - Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C78.4 - Secondary malignant neoplasm of small intestine
C78.7 - Secondary malignant neoplasm of liver and intrahepatic bile duct
C78.80 - Secondary malignant neoplasm of unspecified digestive organ
C78.89 - Secondary malignant neoplasm of other digestive organs
C7A.010 - Malignant carcinoid tumor of the duodenum
C7A.011 - Malignant carcinoid tumor of the jejunum
C7A.019 - Malignant carcinoid tumor of the small intestine, unspecified portion
C7A.092 - Malignant carcinoid tumor of the stomach
C7A.094 - Malignant carcinoid tumor of the foregut, unspecified
C7A.098 - Malignant carcinoid tumors of other sites
C7A.1 - Malignant poorly differentiated neuroendocrine tumors
C7A.8 - Other malignant neuroendocrine tumors
C7B.01 - Secondary carcinoid tumors of distant lymph nodes
C7B.02 - Secondary carcinoid tumors of liver
C80.0 - Disseminated malignant neoplasm, unspecified
C80.1 - Malignant (primary) neoplasm, unspecified
D00.1 - Carcinoma in situ of esophagus
D00.2 - Carcinoma in situ of stomach
D01.40 - Carcinoma in situ of unspecified part of intestine
D01.49 - Carcinoma in situ of other parts of intestine
D01.7 - Carcinoma in situ of other specified digestive organs
D01.9 - Carcinoma in situ of digestive organ, unspecified
D13.0 - Benign neoplasm of esophagus
D13.1 - Benign neoplasm of stomach
D13.2 - Benign neoplasm of duodenum
D13.30 - Benign neoplasm of unspecified part of small intestine
D13.39 - Benign neoplasm of other parts of small intestine
D13.6 - Benign neoplasm of pancreas
D13.99 - Benign neoplasm of ill-defined sites within the digestive system
D21.4 - Benign neoplasm of connective and other soft tissue of abdomen
D37.1 - Neoplasm of uncertain behavior of stomach
D37.2 - Neoplasm of uncertain behavior of small intestine
D37.3 - Neoplasm of uncertain behavior of appendix
D37.4 - Neoplasm of uncertain behavior of colon
D37.5 - Neoplasm of uncertain behavior of rectum
D37.6 - Neoplasm of uncertain behavior of liver, gallbladder and bile ducts
D37.8 - Neoplasm of uncertain behavior of other specified digestive organs
D37.9 - Neoplasm of uncertain behavior of digestive organ, unspecified
D3A.010 - Benign carcinoid tumor of the duodenum
D3A.011 - Benign carcinoid tumor of the jejunum
D3A.019 - Benign carcinoid tumor of the small intestine, unspecified portion
D3A.092 - Benign carcinoid tumor of the stomach
D3A.094 - Benign carcinoid tumor of the foregut, unspecified
D48.3 - Neoplasm of uncertain behavior of retroperitoneum
D48.4 - Neoplasm of uncertain behavior of peritoneum
D49.0 - Neoplasm of unspecified behavior of digestive system
D49.89 - Neoplasm of unspecified behavior of other specified sites
K22.81 - Esophageal polyp
K22.82 - Esophagogastric junction polyp
K31.7 - Polyp of stomach and duodenum
Q85.82 - Other Cowden syndrome
Q85.83 - Von Hippel-Lindau syndrome
Q85.89 - Other phakomatoses, not elsewhere classified
R10.20 - Pelvic and perineal pain unspecified side
R10.21 - Pelvic and perineal pain right side
R10.22 - Pelvic and perineal pain left side
R10.23 - Pelvic and perineal pain bilateral
R10.24 - Suprapubic pain
R10.85 - Abdominal pain of multiple sites
R16.0 - Hepatomegaly, not elsewhere classified
R16.2 - Hepatomegaly with splenomegaly, not elsewhere classified
R19.01 - Right upper quadrant abdominal swelling, mass and lump
R19.02 - Left upper quadrant abdominal swelling, mass and lump
R19.03 - Right lower quadrant abdominal swelling, mass and lump
R19.04 - Left lower quadrant abdominal swelling, mass and lump
R19.05 - Periumbilic swelling, mass or lump
R19.06 - Epigastric swelling, mass or lump
R19.09 - Other intra-abdominal and pelvic swelling, mass and lump
R22.2 - Localized swelling, mass and lump, trunk
T18.3XXD - Foreign body in small intestine, subsequent encounter
T18.3XXS - Foreign body in small intestine, sequela
T18.8XXD - Foreign body in other parts of alimentary tract, subsequent encounter
T18.9XXD - Foreign body of alimentary tract, part unspecified, subsequent encounter
T18.9XXS - Foreign body of alimentary tract, part unspecified, sequela
T54.1X1D - Toxic effect of other corrosive organic compounds, accidental (unintentional), subsequent encounter
T54.1X1S - Toxic effect of other corrosive organic compounds, accidental (unintentional), sequela
T54.1X2D - Toxic effect of other corrosive organic compounds, intentional self-harm, subsequent encounter
T54.1X2S - Toxic effect of other corrosive organic compounds, intentional self-harm, sequela
T54.1X3D - Toxic effect of other corrosive organic compounds, assault, subsequent encounter
T54.1X3S - Toxic effect of other corrosive organic compounds, assault, sequela
T54.1X4D - Toxic effect of other corrosive organic compounds, undetermined, subsequent encounter
T54.1X4S - Toxic effect of other corrosive organic compounds, undetermined, sequela
T54.2X1D - Toxic effect of corrosive acids and acid-like substances, accidental (unintentional), subsequent encounter
T54.2X1S - Toxic effect of corrosive acids and acid-like substances, accidental (unintentional), sequela
T54.2X2D - Toxic effect of corrosive acids and acid-like substances, intentional self-harm, subsequent encounter
T54.2X2S - Toxic effect of corrosive acids and acid-like substances, intentional self-harm, sequela
T54.2X3D - Toxic effect of corrosive acids and acid-like substances, assault, subsequent encounter
T54.2X3S - Toxic effect of corrosive acids and acid-like substances, assault, sequela
T54.2X4D - Toxic effect of corrosive acids and acid-like substances, undetermined, subsequent encounter
T54.2X4S - Toxic effect of corrosive acids and acid-like substances, undetermined, sequela
T54.3X1D - Toxic effect of corrosive alkalis and alkali-like substances, accidental (unintentional), subsequent encounter
T54.3X1S - Toxic effect of corrosive alkalis and alkali-like substances, accidental (unintentional), sequela
T54.3X2D - Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, subsequent encounter
T54.3X2S - Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, sequela
T54.3X3D - Toxic effect of corrosive alkalis and alkali-like substances, assault, subsequent encounter
T54.3X3S - Toxic effect of corrosive alkalis and alkali-like substances, assault, sequela
T54.3X4D - Toxic effect of corrosive alkalis and alkali-like substances, undetermined, subsequent encounter
T54.3X4S - Toxic effect of corrosive alkalis and alkali-like substances, undetermined, sequela
T54.91XD - Toxic effect of unspecified corrosive substance, accidental (unintentional), subsequent encounter
T54.91XS - Toxic effect of unspecified corrosive substance, accidental (unintentional), sequela
T54.92XD - Toxic effect of unspecified corrosive substance, intentional self-harm, subsequent encounter
T54.92XS - Toxic effect of unspecified corrosive substance, intentional self-harm, sequela
T54.93XD - Toxic effect of unspecified corrosive substance, assault, subsequent encounter
T54.93XS - Toxic effect of unspecified corrosive substance, assault, sequela
T54.94XD - Toxic effect of unspecified corrosive substance, undetermined, subsequent encounter
T54.94XS - Toxic effect of unspecified corrosive substance, undetermined, sequela
T57.1X1D - Toxic effect of phosphorus and its compounds, accidental (unintentional), subsequent encounter
T57.1X1S - Toxic effect of phosphorus and its compounds, accidental (unintentional), sequela
T57.1X2D - Toxic effect of phosphorus and its compounds, intentional self-harm, subsequent encounter
T57.1X2S - Toxic effect of phosphorus and its compounds, intentional self-harm, sequela
T57.1X3D - Toxic effect of phosphorus and its compounds, assault, subsequent encounter
T57.1X3S - Toxic effect of phosphorus and its compounds, assault, sequela
T57.1X4D - Toxic effect of phosphorus and its compounds, undetermined, subsequent encounter
T57.1X4S - Toxic effect of phosphorus and its compounds, undetermined, sequela
T73.0XXD - Starvation, subsequent encounter
T73.0XXS - Starvation, sequela
Z86.003 - Personal history of in-situ neoplasm of oral cavity, esophagus and stomach
Z86.004 - Personal history of in-situ neoplasm of other and unspecified digestive organs
Related CPT Codes
CPT Codes
43238 - Complete Billing & Coding Guide for EGD with EUS-Guided Fine Needle Aspiration
43239 - Complete Billing & Coding Guide for EGD with Biopsy
43244 - Complete Billing & Coding Guide for EGD with Band Ligation of Esophageal and Gastric Varices
43245 - Complete Billing & Coding Guide for EGD with Dilation of Gastric or Duodenal Strictures
43248 - Complete Billing & Coding Guide for EGD with Guidewire-Assisted Esophageal Dilation
43249 - Complete Billing & Coding Guide for EGD With Esophageal Balloon Dilation
43251 - Complete Billing & Coding Guide for EGD With Snare Removal of Lesions
43254 - Complete Billing & Coding Guide for Endoscopic Mucosal Resection (EMR)
43255 - Complete Billing & Coding Guide for EGD With Control of Bleeding
43237 - Complete Billing & Coding Guide for EGD with Endoscopic Ultrasound Examination